Magnesium

With peptides

Magnesium functions as foundational mineral support across peptide protocols rather than as a mechanism-specific peptide partner. Sleep-related contexts (GH-secretagogue peptides like CJC-1295 and ipamorelin typically dosed pre-bed for GH pulse alignment) are the context in which magnesium's reported sleep-support role is most relevant. Healing peptides like BPC-157 appear alongside magnesium's broader metabolic role in some protocols.

With supplements

1. Vitamin D3 — magnesium is the cofactor for vitamin D activation enzymes; adequate magnesium status is reported as required for normal vitamin D response.
2. Zinc — both minerals are commonly deficient together; labels commonly note the two compete for absorption sites, hence separate-or-with-food dosing guidance.
3. Calcium — vitamin D-mediated calcium absorption requires the magnesium cofactor. NIH ODS interaction data note the two compete for absorption when dosed together; product labels commonly recommend separating by 2+ hours.
4. ZMA (Zinc + Magnesium + B6) — a bedtime supplement formulation combining magnesium with zinc and B6.
5. Melatonin — a different mechanism (circadian) than magnesium (GABA); the two appear together in sleep-stacking products.
6. Glycine — appears in sleep/recovery products alongside magnesium's GABA-related effects.
7. L-theanine — a complementary calming/anxiety mechanism used alongside magnesium in some products.
8. Electrolyte powders — most formulations contain modest magnesium amounts.
9. Creatine — a different mechanism, appearing together in general athletic-stacking products.

With lifestyle factors

1. Dietary magnesium sources. Per NIH ODS food-content data: leafy greens, nuts, seeds (pumpkin seeds especially), whole grains, legumes, and dark chocolate. The 320–420 mg/day RDA can be met from diet, though NIH ODS-cited surveys report many people fall short.
2. Factors increasing magnesium losses. Alcohol, caffeine (modest effect), diuretics, and heavy sweating are reported to increase magnesium losses.
3. Stress. Chronic stress is reported to deplete magnesium status.
4. Sleep hygiene. In the Abbasi et al. 2012 trial context, magnesium was studied as an adjunct rather than a substitute for sleep-hygiene practices.
5. Hydration. Adequate water intake is reported to support magnesium function and reduce constipation independent of supplementation.
6. Cardiovascular and DASH-style diet. Zhang et al. 2016's BP findings are discussed alongside potassium, dietary nitrate, and the broader Mediterranean/DASH eating pattern.
7. Athletes and high sweat losses. Increased magnesium requirements are reported during heavy training blocks and heat exposure.

Common (mostly transient)

1. Diarrhea and loose stools. Reported as dose- and form-dependent (oxide most, glycinate least). The NIH ODS 350 mg/day supplemental UL is set by this laxative threshold; product labels commonly note lower-dose or glycinate-form options reduce this effect.
2. Mild GI discomfort is reported at high doses or on an empty stomach.
3. No documented serious adverse events are reported at standard supplemental doses in healthy adults.

Less common (watch-list)

1. Kidney disease. NIH ODS reports impaired magnesium clearance and hypermagnesemia risk in reduced or lost kidney function; nephrology coordination is the standard guidance in this context.
2. Hypermagnesemia. Reported as rare with normal kidney function but serious when it occurs — muscle weakness, hypotension, respiratory depression, and cardiac arrest at extreme levels — almost exclusively in kidney failure or massive-overdose contexts.
3. Heart block / bradycardia. High-dose magnesium is theorized to worsen conduction abnormalities; this is not generally reported as a concern at standard supplemental doses.
4. Pregnancy and breastfeeding. Standard supplemental doses are generally reported as safe; obstetric coordination is standard guidance for higher doses.
5. Myasthenia gravis. Magnesium is reported to potentially worsen neuromuscular weakness in this condition; neurology coordination is the standard guidance.

Drug and supplement interactions (NIH ODS)

1. Antibiotics (quinolones, tetracyclines). NIH ODS reports magnesium forms insoluble complexes with these antibiotic classes, reducing absorption; the fact sheet recommends these antibiotics be taken at least 2 hours before or 4–6 hours after a magnesium-containing supplement.
2. Bisphosphonates (osteoporosis medications). NIH ODS reports magnesium decreases oral bisphosphonate absorption and recommends separating dosing by at least 2 hours.
3. Diuretics. NIH ODS reports loop and thiazide diuretics increase magnesium losses, while potassium-sparing diuretics reduce magnesium excretion.
4. Proton pump inhibitors (PPIs). FDA safety review, per NIH ODS, links long-term PPI use (typically over a year) to hypomagnesemia and recommends clinicians consider checking serum magnesium before and periodically during long-term PPI treatment.
5. Calcium supplements. Reported to compete for absorption; separating dosing by 2+ hours is the common label guidance.
6. Antihypertensive medications — a modest additive BP-lowering effect is reported.
7. Diabetes medications — a modest additive glucose-lowering effect is reported.

Glycinate vs citrate vs oxide vs threonate — which magnesium form is best?

Form selection tracks the target use case. Magnesium glycinate (bisglycinate) is gentle on the GI tract, well-absorbed, and is the form most commonly used for general supplementation and for sleep/anxiety contexts where a laxative effect is unwanted. Magnesium citrate is well-absorbed and produces a mild osmotic laxative effect, which is why it's used when constipation is also a target. Magnesium oxide has poor elemental bioavailability (roughly 4%) but a strong osmotic effect, making it inexpensive and effective specifically for constipation while being a weaker choice for correcting general magnesium status. Magnesium L-threonate is marketed for cognitive applications based on Liu et al. 2010 rodent data showing brain magnesium increases; the human evidence is thin — Liu et al. 2016 is the main human trial, small (n=44) and industry-funded — and the form costs substantially more per mg of elemental magnesium than glycinate or citrate. Magnesium malate combines magnesium with malic acid and appears in fatigue and fibromyalgia contexts.

How much magnesium is typically used?

The NIH Office of Dietary Supplements lists an RDA (total intake including diet) of 320 mg/day for adult women and 420 mg/day for adult men age 31+. Survey data cited in Schwalfenberg & Genuis 2017 indicates 45–68% of US adults fall short of the RDA from diet alone. The NIH ODS supplemental tolerable upper intake level (UL) is 350 mg/day — a figure that applies specifically to magnesium from supplements and medications (where the osmotic/laxative effect becomes limiting), not to dietary magnesium, which has no established toxicity ceiling in people with normal kidney function. For migraine prophylaxis, the Holland/Silberstein et al. 2012 AAN/AHS guideline gives magnesium a Level B (probably effective) rating at doses in the 400–600 mg/day range — above the general supplemental UL, which is why the guideline frames this as a neurology-coordinated protocol. IV magnesium sulfate is used under obstetric supervision for eclampsia/pre-eclampsia seizure prophylaxis. General supplemental doses in trials and product labels commonly fall in the 200–400 mg/day elemental range.

Does the evidence support magnesium for sleep?

The evidence is thinner than magnesium's popular reputation as a sleep aid suggests. The most-cited trial, Abbasi et al. 2012, is a small (n=46) double-blind trial in elderly insomniacs that documented modest sleep-quality improvement at 500 mg/day for 8 weeks. Subsequent RCT replication is limited, and the trial's small sample size limits generalizability. The proposed mechanism — GABA-A receptor potentiation and NMDA antagonism — is biologically plausible but doesn't itself establish clinical effect size. The Abbasi trial dosed participants 1 hour before bedtime. Effect appears more pronounced in participants who were deficient at baseline. This sits in an Emerging/Modest evidence tier rather than Strong.

Does magnesium help with muscle cramps?

For general/idiopathic muscle cramps in adults, the best available evidence says no. Garrison et al. 2020, a Cochrane systematic review of 11 RCTs, found magnesium supplementation did not significantly reduce cramp frequency, intensity, or duration in adults with idiopathic muscle cramps — a negative, high-quality evidence base that runs against magnesium's popular reputation for this indication. The review notes two contexts where the picture differs: pregnancy leg cramps (moderate evidence of benefit) and exercise-associated cramps in people with documented magnesium deficiency (modest evidence). Cramp causality itself is more complex than simple electrolyte depletion, per Schwellnus 2009's critique of the broader cramp-mechanism question, cited in the review's discussion.

Does magnesium help prevent migraines?

This is reported as one of magnesium's better-evidenced applications. Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E — the AAN/AHS Quality Standards Subcommittee's 2012 guideline update on NSAIDs and complementary treatments for episodic migraine prevention — gives magnesium a Level B rating (probably effective) alongside riboflavin, feverfew (MIG-99), and several NSAIDs, based on the panel's review of 49 Class I/II trials. The guideline's companion paper (Silberstein et al. 2012, covering pharmacologic treatments) is a separate document and does not itself address magnesium. Trials underlying the Level B rating generally used 400–600 mg/day elemental magnesium over 8–12 weeks. Proposed mechanisms include NMDA receptor modulation, vasodilation, and effects on platelet aggregation; migraine sufferers are reported to have lower magnesium status on average than non-sufferers. The guideline's dose range exceeds the general supplemental UL of 350 mg/day, which the guideline frames as a neurology-coordinated protocol rather than routine self-supplementation. Citrate, glycinate, and oxide forms have all been used in the underlying trials. The effect reported is preventive rather than abortive — magnesium taken during an active migraine attack is not shown to stop it, though IV magnesium sulfate appears in some emergency-department migraine protocols outside this guideline's scope.

What does the evidence say about magnesium L-threonate and cognition?

The mechanism is well-described, but human evidence is thin and the form is expensive. Magnesium L-threonate was developed specifically to cross the blood-brain barrier and raise brain magnesium concentrations. Liu et al. 2010 documented brain magnesium increases alongside learning/memory improvements in aged rats. Liu et al. 2016 — titled "Efficacy and safety of MMFS-01, a synapse density enhancer, for treating cognitive impairment in older adults" — is the most-cited human trial: a randomized, double-blind, placebo-controlled study in 44 older adults with cognitive impairment, reporting modest cognitive improvements, but the sample is small and the trial was industry-funded. Whether magnesium threonate outperforms equivalent elemental-magnesium doses of other forms in healthy users has not been characterized in head-to-head trials. The form's per-mg cost runs 5–10x higher than glycinate or citrate on typical retail pricing.

What effect does magnesium have on blood pressure?

A modest one, per Zhang et al. 2016, a meta-analysis of 34 RCTs (2,028 participants) that documented a systolic BP reduction of roughly 2 mmHg and diastolic reduction of roughly 1.78 mmHg with magnesium supplementation, with a larger effect reported in hypertensive populations and at doses of 300+ mg/day. The proposed mechanism is magnesium's action as a natural calcium-channel blocker, regulating vascular smooth muscle tone. This effect size is modest relative to antihypertensive medication classes and is reported as additive to lifestyle interventions (DASH diet, exercise, weight management, potassium intake) rather than as a standalone BP intervention.

What safety considerations and contraindications are reported for magnesium?

The NIH Office of Dietary Supplements and FDA-reviewed drug-interaction data describe magnesium as generally well-tolerated at standard supplemental doses in people with normal kidney function, with several documented considerations: (1) the supplemental UL is 350 mg/day, above which osmotic diarrhea becomes the dose-limiting effect — this UL doesn't apply to dietary intake; (2) in kidney disease, magnesium clearance is impaired, and the NIH ODS fact sheet notes reduced or lost ability to remove excess magnesium in reduced kidney function or kidney failure; (3) the NIH ODS fact sheet reports that magnesium forms insoluble complexes with tetracycline and quinolone antibiotics, and recommends these be taken at least 2 hours before or 4–6 hours after a magnesium-containing supplement; (4) the same fact sheet reports that magnesium-rich supplements can decrease oral bisphosphonate absorption, with dosing separated by at least 2 hours; (5) FDA safety review, per the NIH ODS fact sheet, found long-term proton pump inhibitor use (typically over a year) associated with hypomagnesemia, and advises clinicians to consider checking serum magnesium periodically during long-term PPI therapy; (6) hypermagnesemia (magnesium toxicity) is described as rare in people with normal kidney function but serious when it occurs — causing muscle weakness, hypotension, and respiratory depression — and is reported almost exclusively in kidney failure or massive-overdose contexts.